



## [EACR Congress 2024: Innovative Cancer Science](#)

**Organizers:** The European Association for Cancer Research (EACR)

**Title of conference:** EACR Congress 2024: Innovative Cancer Science

**Date & Location:** 10 – 13 June 2024 | Rotterdam, Netherlands

**Short description:** The 2024 Annual Congress of the European Association for Cancer Research is a four-day meeting dedicated to basic, preclinical, and translational cancer research across a wide breadth of topics. It will highlight the latest findings and bring together the cancer research community to inspire innovation and build knowledge, connections, and collaborations. As well as cutting-edge scientific content, the Congress will feature a large industry exhibition with symposia and spotlight talks, Meet the Expert sessions, keynote lectures from renowned names in cancer research, 'Career Discovery' roundtable sessions for early-career researchers, a vast poster display with timetabled defence sessions, a ticketed conference celebration dinner, and many opportunities for networking.

Topics to be covered include: modulating the tumour microenvironment; drug resistance; mechanism-based clinical trials; precision cancer medicine in the post-genomic era; senescence, dormancy, and related cell states; metabolism and cancer; cell-based therapies; spatial analysis of tumours/spatial transcriptomics; mechanical forces of cancer; mechanisms of tumour metastases; targeting mitochondria in cancer; liquid biopsies; drugging tumour suppressor genes; imaging the tumour microenvironment; making cold tumours hot; drugging the RAS Pathway; modelling cancer; ageing, gender, and cancer; and more.

This congress will be suitable for cancer researchers of any career stage, working in either academia or industry, who wish to further their career and make connections by attending high-quality scientific talks and networking sessions.

### **Deadlines:**

Travel grant application deadline: 04 March 2024

Abstract submission deadline: 04 March 2024

Early-rate registration deadline: 29 April 2024

Late-breaking abstract submission deadline: 10 May 2024

Regular-rate registration deadline: 27 May 2024

**Contact Person:** New Way Management <[eacr@newway-management.com](mailto:eacr@newway-management.com)>

**Speakers:** Leila Akkari, Chiara Ambrogio, Michael A. Angelo, Alberto Bardelli, René Bernards, Zuhir Bodalal Elkarghal, Arkaitz Carracedo, Maria Casanova-Acebes, Karen M. Cichowski, Sarah-Jane Dawson, Luis Alberto Diaz, Caroline Dive, Ayelet Erez, Neta Erez, Janine Erler, Sarah-Maria Fendt, Peter Friedl, Susan Galbraith, Payam Gammage, Giovanni Germano, Richard J. Gilbertson, Jacky G. Goetz, Greg Hannon, Marco Hofmann, Maija Hollmén, Claus Jorgensen, Bozena Kaminska-Kaczmarek, Valery Krizhanovsky, Pia Kvistborg, David Lane, Ana Luisa Correia, Berta López Sánchez-Laorden, Ilaria Malanchi, Florent Mouliere, Benjamin G. Neel, Sergio Quezada, Anne Rios, Nitzan Rosenfeld, Erik Sahai, Yardena Samuels, Jean-Emmanuel Sarry, Ruth Scherz-Shouval, Clemens A. Schmitt, Giorgio Scita, Marisol S. Soengas, Pierre Sonveaux, Charles Swanton, Daniela S. Thommen, Itay Tirosh, Eric Tran, Samra Turajlic, Amaya Viros, Ashani Weeraratna, Alana L. Welm, Sara Zanivan, Jessica Zucman-Rossi, Hugues de Thé, Karin de Visser, and Matthew vander Heiden

**Keywords:** EACR Congress, cancer research conference, oncology, the tumour microenvironment, drug resistance, precision cancer medicine, genomics, transcriptomics, cell senescence, cell dormancy, cancer metabolism, cell-based therapies, spatial tumour analysis, tumour metastasis, targeting mitochondria, liquid biopsies, the RAS Pathway, cold tumours, hot tumours, tumour suppressor genes, cancer models, microphage reprogramming, immunotherapy, RNA-binding proteins, cell heterogeneity, tumour heterogeneity, computational pathology, molecular mechanisms of cancer, cancer therapies, anti-tumour stroma, cell metabolism, tissue fluidification, stromal plasticity, immune plasticity, cell plasticity, cancer and aging, cancer and gender, DNA mutations, next-generation assays, tumour therapy response, p53 response, cancer progression, non-invasive imaging techniques, AI, radiogenomics, 19F MRI, personalised cell therapy, combination therapies, KRAS-driven cancers, intrinsic resistance, acquired resistance, oncogene-dependence, t-cell immunity, organoid models, the tumour macroenvironment, basic cancer research, translational cancer research, preclinical cancer research

